Author:
Kaul Sanjay,Bolger Ann F.,Herrington David,Giugliano Robert P.,Eckel Robert H.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference46 articles.
1. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
2. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
3. Rosiglitazone: A Thunderstorm from Scarce and Fragile Data
4. Advisory Committee Briefing Document: Cardiovascular Safety of Rosiglitazone. Philadelphia Pa: GlaxoSmithKline; 2007. Available at: www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-01-sponsor-backgrounder.pdf. Accessed December 12 2009.
5. FDA Briefing Document: Advisory Committee meeting July 30th 2007 to discuss cardiovascular ischemic events with Avandia: Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-FDA-backgrounder.pdf. Accessed December 12 2009.
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献